Skip to main content
Erschienen in: Breast Cancer Research and Treatment 3/2014

01.04.2014 | Epidemiology

Prevalence of breast cancer in thyroid diseases: results of a cross-sectional study of 3,921 patients

verfasst von: Natalie Prinzi, Enke Baldini, Salvatore Sorrenti, Corrado De Vito, Chiara Tuccilli, Antonio Catania, Sabino Carbotta, Renzo Mocini, Carmela Coccaro, Angela Nesca, Marta Bianchini, Enrico De Antoni, Massimino D’Armiento, Salvatore Ulisse

Erschienen in: Breast Cancer Research and Treatment | Ausgabe 3/2014

Einloggen, um Zugang zu erhalten

Abstract

Results from national cancer registries reveal an association of thyroid cancers with extra-thyroidal malignancies. In this study, we evaluated the prevalence of breast cancer (BC) in women affected by both benign and malignant thyroid diseases (TD) in comparison to the general population. To this end, 3,921 female patients from central and southern regions of Italy were evaluated. Age-matched analysis of the prevalence of BC was carried out after dividing the patients into three diagnostic categories: (1) 1,149 patients with non-nodular TD; (2) 2350 patients with nodular TD; (3) 422 patients affected by differentiated thyroid cancers. Furthermore, the patients were grouped according to the absence (2,344 patients) or presence (1,453 patients) of anti-thyroglobulin (TgAb) and/or anti-thyroperoxidase (TPOAb) or anti-TSH receptor auto-antibodies (124 patients). BC prevalence in TD patients as a whole was significantly higher compared to the general population, with an odds ratio (OR) of 3.33. Age-matched analysis showed that the risk of a BC in TD patients was higher in younger patients (age 0–44 years), with an OR of 15.24, which decreased with increasing age. Patients without thyroid auto-antibodies showed a higher OR for BC (p = 0.0005) than TD patients with TgAb and/or TPOAb. The results demonstrate that women affected by either benign or malignant thyroid disease have a significantly greater risk of BC, which is higher at a younger age. Furthermore, thyroid auto-antibodies appear to be protective against BC. These findings may contribute to the identification of common genetic and environmental factors underlying this disease association.
Literatur
2.
Zurück zum Zitat Gharib M, Gharib H (2011) Guidelines for the diagnosis and management of thyroid nodules. Thyroid Int 1:3–11 Gharib M, Gharib H (2011) Guidelines for the diagnosis and management of thyroid nodules. Thyroid Int 1:3–11
3.
Zurück zum Zitat Mehanna HM, Jain A, Morton RP, Watkinson J, Shaha A (2009) Investigating the thyroid nodule. BMJ 338:b733PubMedCrossRef Mehanna HM, Jain A, Morton RP, Watkinson J, Shaha A (2009) Investigating the thyroid nodule. BMJ 338:b733PubMedCrossRef
4.
Zurück zum Zitat Trimboli P, Ulisse S, Graziano FM, Marzullo A, Ruggieri M, Calvanese A, Piccirilli F, Cavaliere R, Fumarola A, D’Armiento M (2006) Trend in thyroid carcinoma size, age at diagnosis and histology in a retrospective study of 500 cases diagnosed over 20 years. Thyroid 16:1151–1155PubMedCrossRef Trimboli P, Ulisse S, Graziano FM, Marzullo A, Ruggieri M, Calvanese A, Piccirilli F, Cavaliere R, Fumarola A, D’Armiento M (2006) Trend in thyroid carcinoma size, age at diagnosis and histology in a retrospective study of 500 cases diagnosed over 20 years. Thyroid 16:1151–1155PubMedCrossRef
5.
Zurück zum Zitat Paschke R (2011) Molecular pathogenesis of nodular goiter. Langenbecks Arch Surg 396:1127–1136PubMedCrossRef Paschke R (2011) Molecular pathogenesis of nodular goiter. Langenbecks Arch Surg 396:1127–1136PubMedCrossRef
6.
Zurück zum Zitat Nikiforov YE, Biddinger PW, Thompson LDR (2009) Diagnostic pathology and molecular genetics of the thyroid. Wolters Kluwer–Lippincott Williams & Wilkins, Philadelphia Nikiforov YE, Biddinger PW, Thompson LDR (2009) Diagnostic pathology and molecular genetics of the thyroid. Wolters Kluwer–Lippincott Williams & Wilkins, Philadelphia
8.
Zurück zum Zitat Lal G, Groff M, Howe JR, Weigel RJ, Sugg SL, Lynch CF (2012) Risk of subsequent primary thyroid cancer after another malignancy: latency trends in a population-based study. Ann Surg Oncol 19:1887–1896PubMedCrossRef Lal G, Groff M, Howe JR, Weigel RJ, Sugg SL, Lynch CF (2012) Risk of subsequent primary thyroid cancer after another malignancy: latency trends in a population-based study. Ann Surg Oncol 19:1887–1896PubMedCrossRef
9.
Zurück zum Zitat Taylor AJ, Croft AP, Palace AM, Winter DL, Reulen RC, Stiller CA, Stevens MC, Hawkins MM (2009) Risk of thyroid cancer in survivors of childhood cancer: results from the british childhood cancer survivor study. Int J Cancer 125:2400–2405PubMedCrossRef Taylor AJ, Croft AP, Palace AM, Winter DL, Reulen RC, Stiller CA, Stevens MC, Hawkins MM (2009) Risk of thyroid cancer in survivors of childhood cancer: results from the british childhood cancer survivor study. Int J Cancer 125:2400–2405PubMedCrossRef
10.
Zurück zum Zitat Bhatti P, Veiga LH, Ronckers CM, Sigurdson AJ, Stovall M, Smith SA, Weathers R, Leisenring W, Mertens AC, Hammond S, Friedman DL, Neglia JP, Meadows AT, Donaldson SS, Sklar CA, Robison LL, Inskip PD (2010) Risk of second primary thyroid cancer after radiotherapy for a childhood cancer in a large cohort study: an update from the childhood cancer survivor study. Radiat Res 174:741–752PubMedCentralPubMedCrossRef Bhatti P, Veiga LH, Ronckers CM, Sigurdson AJ, Stovall M, Smith SA, Weathers R, Leisenring W, Mertens AC, Hammond S, Friedman DL, Neglia JP, Meadows AT, Donaldson SS, Sklar CA, Robison LL, Inskip PD (2010) Risk of second primary thyroid cancer after radiotherapy for a childhood cancer in a large cohort study: an update from the childhood cancer survivor study. Radiat Res 174:741–752PubMedCentralPubMedCrossRef
11.
Zurück zum Zitat Armstrong GT, Stovall M, Robison LL (2010) Long-term effects of radiation exposure among adult survivors of childhood cancer: results from the childhood cancer survivor study. Radiat Res 174:840–850PubMedCentralPubMedCrossRef Armstrong GT, Stovall M, Robison LL (2010) Long-term effects of radiation exposure among adult survivors of childhood cancer: results from the childhood cancer survivor study. Radiat Res 174:840–850PubMedCentralPubMedCrossRef
12.
Zurück zum Zitat Canchola AJ, Horn-Ross PL, Purdie DM (2006) Risk of second primary malignancies in women with papillary thyroid cancer. Am J Epidemiol 163:521–527PubMedCrossRef Canchola AJ, Horn-Ross PL, Purdie DM (2006) Risk of second primary malignancies in women with papillary thyroid cancer. Am J Epidemiol 163:521–527PubMedCrossRef
13.
Zurück zum Zitat Sawka AM, Thabane L, Parlea L, Ibrahim-Zada I, Tsang RW, Brierley JD, Straus S, Ezzat S, Goldstein DP (2009) Second primary malignancy risk after radioactive iodine treatment for thyroid cancer: a systematic review and meta-analysis. Thyroid 19:451–457PubMedCrossRef Sawka AM, Thabane L, Parlea L, Ibrahim-Zada I, Tsang RW, Brierley JD, Straus S, Ezzat S, Goldstein DP (2009) Second primary malignancy risk after radioactive iodine treatment for thyroid cancer: a systematic review and meta-analysis. Thyroid 19:451–457PubMedCrossRef
14.
Zurück zum Zitat Brown AP, Chen J, Hitchcock YI, Szabo A, Shrieve DC, Tward JD (2008) The risk of second primary malignancy up to three decades after the treatment of differentiated thyroid cancer. J Clin Endocrinol Metab 93:504–515PubMedCrossRef Brown AP, Chen J, Hitchcock YI, Szabo A, Shrieve DC, Tward JD (2008) The risk of second primary malignancy up to three decades after the treatment of differentiated thyroid cancer. J Clin Endocrinol Metab 93:504–515PubMedCrossRef
15.
Zurück zum Zitat Berthe E, Henty-Amar M, Michels J-J, Rame JP, Berthet P, Babin E, Icard P, Samama G, Galateau-Sallé F, Mahoudeau J, Bardet S (2004) Risk of second primary cancer following differentiated thyroid cancer. Eur J Nucl Med Mol Imag 31:685–691CrossRef Berthe E, Henty-Amar M, Michels J-J, Rame JP, Berthet P, Babin E, Icard P, Samama G, Galateau-Sallé F, Mahoudeau J, Bardet S (2004) Risk of second primary cancer following differentiated thyroid cancer. Eur J Nucl Med Mol Imag 31:685–691CrossRef
16.
Zurück zum Zitat Rubino C, de Vathaire F, Dottorini ME, Hall P, Schvartz C, Couette JE, Dondon MG, Abbas MT, Langlois C, Schlumberger M (2003) Second primary malignancies in thyroid cancer patients. Br J Cancer 89:1638–1644PubMedCentralPubMedCrossRef Rubino C, de Vathaire F, Dottorini ME, Hall P, Schvartz C, Couette JE, Dondon MG, Abbas MT, Langlois C, Schlumberger M (2003) Second primary malignancies in thyroid cancer patients. Br J Cancer 89:1638–1644PubMedCentralPubMedCrossRef
17.
Zurück zum Zitat Subramanian S, Goldstein DP, Parlea L, Thabane L, Ezzat S, Ibrahim-Zada I, Straus S, Brierley JD, Tsang RW, Gafni A, Rotstein L, Sawka AM (2007) Second primary malignancy risk in thyroid cancer survivors: a systematic review and meta-analysis. Thyroid 17:1277–1288PubMedCrossRef Subramanian S, Goldstein DP, Parlea L, Thabane L, Ezzat S, Ibrahim-Zada I, Straus S, Brierley JD, Tsang RW, Gafni A, Rotstein L, Sawka AM (2007) Second primary malignancy risk in thyroid cancer survivors: a systematic review and meta-analysis. Thyroid 17:1277–1288PubMedCrossRef
18.
Zurück zum Zitat Ronckers CM, McCarron P, Ron E (2005) Thyroid cancer and multiple primary tumors in the SEER cancer registries. Int J Cancer 117:281–288PubMedCrossRef Ronckers CM, McCarron P, Ron E (2005) Thyroid cancer and multiple primary tumors in the SEER cancer registries. Int J Cancer 117:281–288PubMedCrossRef
19.
Zurück zum Zitat Chuang SC, Hashibe M, Yu GP, Le AD, Cao W, Hurwitz EL, Rao JY, Neugut AI, Zhang ZF (2006) Radiotherapy for primary thyroid cancer as a risk factor for second primary cancers. Cancer Lett 238:42–52PubMedCrossRef Chuang SC, Hashibe M, Yu GP, Le AD, Cao W, Hurwitz EL, Rao JY, Neugut AI, Zhang ZF (2006) Radiotherapy for primary thyroid cancer as a risk factor for second primary cancers. Cancer Lett 238:42–52PubMedCrossRef
20.
Zurück zum Zitat Sandeep TC, Strachan MWJ, Reynolds RM, Brewster DH, Scélo G, Pukkala E, Hemminki K, Anderson A, Tracey E, Friis S, McBride ML, Kee-Seng C, Pompe-Kirn V, Kliewer EV, Tonita JM, Jonasson JG, Martos C, Boffetta P, Brennan P (2006) Second primary cancers in thyroid cancer patients: a multinational record linkage study. J Clin Endocrinol Metab 91:1819–1825PubMedCrossRef Sandeep TC, Strachan MWJ, Reynolds RM, Brewster DH, Scélo G, Pukkala E, Hemminki K, Anderson A, Tracey E, Friis S, McBride ML, Kee-Seng C, Pompe-Kirn V, Kliewer EV, Tonita JM, Jonasson JG, Martos C, Boffetta P, Brennan P (2006) Second primary cancers in thyroid cancer patients: a multinational record linkage study. J Clin Endocrinol Metab 91:1819–1825PubMedCrossRef
21.
Zurück zum Zitat Hardefeldt PJ, Eslick GD, Edirimanne S (2012) Benign thyroid disease is associated with breast cancer: a meta-analysis. Breast Cancer Res Treat 133:1169–1177PubMedCrossRef Hardefeldt PJ, Eslick GD, Edirimanne S (2012) Benign thyroid disease is associated with breast cancer: a meta-analysis. Breast Cancer Res Treat 133:1169–1177PubMedCrossRef
22.
Zurück zum Zitat Sarlis NJ, Gourgiotis L, Pucino F, Tollis GJ (2002) Lack of association between Hashimoto thyroiditis and breast cancer: a quantitative research synthesis. Hormones 1:35–41PubMedCrossRef Sarlis NJ, Gourgiotis L, Pucino F, Tollis GJ (2002) Lack of association between Hashimoto thyroiditis and breast cancer: a quantitative research synthesis. Hormones 1:35–41PubMedCrossRef
23.
Zurück zum Zitat Tosovic A, Becker C, Bondeson AG, Bondeson L, Ericsson UB, Malm J, Manjer J (2012) Prospectively measured thyroid hormones and thyroid peroxidase antibodies in relation to breast cancer risk. Int J Cancer 131:2126–2133PubMedCrossRef Tosovic A, Becker C, Bondeson AG, Bondeson L, Ericsson UB, Malm J, Manjer J (2012) Prospectively measured thyroid hormones and thyroid peroxidase antibodies in relation to breast cancer risk. Int J Cancer 131:2126–2133PubMedCrossRef
24.
Zurück zum Zitat Garber JR, Cobin RH, Gharib H, Hennessey JV, Klein I, Mechanick JI, Pessah-Pollack R, Singer PA, Woeber KA, American Association Of Clinical Endocrinologists And American Thyroid Association Taskforce On Hypothyroidism In Adults (2012) Clinical practice guidelines for hypothyroidism in adults: cosponsored by the American Association of Clinical Endocrinologists and the American Thyroid Association. Thyroid 22:1200–1235PubMedCrossRef Garber JR, Cobin RH, Gharib H, Hennessey JV, Klein I, Mechanick JI, Pessah-Pollack R, Singer PA, Woeber KA, American Association Of Clinical Endocrinologists And American Thyroid Association Taskforce On Hypothyroidism In Adults (2012) Clinical practice guidelines for hypothyroidism in adults: cosponsored by the American Association of Clinical Endocrinologists and the American Thyroid Association. Thyroid 22:1200–1235PubMedCrossRef
25.
Zurück zum Zitat Bahn RS, Burch HB, Cooper DS, Garber JR, Greenlee MC, Klein I, Laurberg P, McDougall IR, Montori VM, Rivkees SA, Ross DS, Sosa JA, Stan MN, American Thyroid Association; American Association of Clinical Endocrinologists (2011) Hyperthyroidism and other causes of thyrotoxicosis: management guidelines of the American Thyroid Association and American Association of Clinical Endocrinologists. Endocr Pract 17:456–520PubMedCrossRef Bahn RS, Burch HB, Cooper DS, Garber JR, Greenlee MC, Klein I, Laurberg P, McDougall IR, Montori VM, Rivkees SA, Ross DS, Sosa JA, Stan MN, American Thyroid Association; American Association of Clinical Endocrinologists (2011) Hyperthyroidism and other causes of thyrotoxicosis: management guidelines of the American Thyroid Association and American Association of Clinical Endocrinologists. Endocr Pract 17:456–520PubMedCrossRef
27.
Zurück zum Zitat Garber JR, Cobin RH, Gharib H, Hennessey JV, Klein I, Mechanick JI, Pessah-Pollack R, Singer PA, Woeber KA, American Association of Clinical Endocrinologists and American Thyroid Association Taskforce on Hypothyroidism in Adults (2012) Clinical practice guidelines for hypothyroidism in adults: cosponsored by the American Association of Clinical Endocrinologists and the American Thyroid Association. Endocr Pract 18:988–1028PubMedCrossRef Garber JR, Cobin RH, Gharib H, Hennessey JV, Klein I, Mechanick JI, Pessah-Pollack R, Singer PA, Woeber KA, American Association of Clinical Endocrinologists and American Thyroid Association Taskforce on Hypothyroidism in Adults (2012) Clinical practice guidelines for hypothyroidism in adults: cosponsored by the American Association of Clinical Endocrinologists and the American Thyroid Association. Endocr Pract 18:988–1028PubMedCrossRef
28.
Zurück zum Zitat Trimboli P, Ulisse S, D’Alò M, Solari F, Fumarola A, Ruggieri M, De Antoni E, Catania A, Sorrenti S, Nardi F, D’Armiento M (2008) Analysis of clinical, ultrasound and colour flow-Doppler characteristics in predicting malignancy in follicular thyroid neoplasms. Clin Endocrinol 69:342–344CrossRef Trimboli P, Ulisse S, D’Alò M, Solari F, Fumarola A, Ruggieri M, De Antoni E, Catania A, Sorrenti S, Nardi F, D’Armiento M (2008) Analysis of clinical, ultrasound and colour flow-Doppler characteristics in predicting malignancy in follicular thyroid neoplasms. Clin Endocrinol 69:342–344CrossRef
29.
Zurück zum Zitat Aghini-Lombardi F, Antonangeli L, Vitti P, Pinchera A (1993) Status of iodine nutrition in Italy. In: Dunn JT, Glinoer D (eds) Delange F. Plenum Press, New York, Iodine Deficiency in Europe. A Continuing Concern., pp 403–408 Aghini-Lombardi F, Antonangeli L, Vitti P, Pinchera A (1993) Status of iodine nutrition in Italy. In: Dunn JT, Glinoer D (eds) Delange F. Plenum Press, New York, Iodine Deficiency in Europe. A Continuing Concern., pp 403–408
30.
Zurück zum Zitat AIRTUM Working Group (2010) Italian cancer figures, report 2010: cancer prevalence in Italy. Patients living with cancer, long term survivors and cured patients. Epidemiol Prev 34:1–188 AIRTUM Working Group (2010) Italian cancer figures, report 2010: cancer prevalence in Italy. Patients living with cancer, long term survivors and cured patients. Epidemiol Prev 34:1–188
31.
Zurück zum Zitat Smyth PP, Shering SG, Kilbane MT, Murray MJ, McDermott EW, Smith DF, O’Higgins NJ (1998) Serum thyroid peroxidase autoantibodies, thyroid volume, and outcome in breast carcinoma. J Clin Endocrinol Metab 83:2711–2716PubMed Smyth PP, Shering SG, Kilbane MT, Murray MJ, McDermott EW, Smith DF, O’Higgins NJ (1998) Serum thyroid peroxidase autoantibodies, thyroid volume, and outcome in breast carcinoma. J Clin Endocrinol Metab 83:2711–2716PubMed
32.
Zurück zum Zitat Shu X, Ji J, Li X, Sundquist J, Sundquist K, Hemminki K (2010) Cancer risk in patients hospitalised for Graves’ disease: a population-based cohort study in Sweden. Br J Cancer 102:1397–1399PubMedCentralPubMedCrossRef Shu X, Ji J, Li X, Sundquist J, Sundquist K, Hemminki K (2010) Cancer risk in patients hospitalised for Graves’ disease: a population-based cohort study in Sweden. Br J Cancer 102:1397–1399PubMedCentralPubMedCrossRef
33.
Zurück zum Zitat Cerbon MA, Pichon MF, Milgrom E (1981) Thyroid hormone receptors in human breast cancer. Cancer Res 41:4167–4173PubMed Cerbon MA, Pichon MF, Milgrom E (1981) Thyroid hormone receptors in human breast cancer. Cancer Res 41:4167–4173PubMed
34.
Zurück zum Zitat Silva JM, Domínguez G, González-Sancho JM, García JM, Silva J, García-Andrade C, Navarro A, Muñoz A, Bonilla F (2002) Expression of thyroid hormone receptor/erbA genes is altered in human breast cancer. Oncogene 21:4307–4316PubMedCrossRef Silva JM, Domínguez G, González-Sancho JM, García JM, Silva J, García-Andrade C, Navarro A, Muñoz A, Bonilla F (2002) Expression of thyroid hormone receptor/erbA genes is altered in human breast cancer. Oncogene 21:4307–4316PubMedCrossRef
35.
Zurück zum Zitat Nogueira CR, Brentani MM (1996) Triiodothyronine mimics the effects of estrogen in breast cancer cell lines. J Steroid Biochem Mol Biol 59:271–279PubMedCrossRef Nogueira CR, Brentani MM (1996) Triiodothyronine mimics the effects of estrogen in breast cancer cell lines. J Steroid Biochem Mol Biol 59:271–279PubMedCrossRef
36.
Zurück zum Zitat Ulisse S, Tata JR (1994) Thyroid hormone and glucocorticoid independently regulate the expression of estrogen receptor in male Xenopus liver cells. Mol Cell Endocrinol 105:45–53PubMedCrossRef Ulisse S, Tata JR (1994) Thyroid hormone and glucocorticoid independently regulate the expression of estrogen receptor in male Xenopus liver cells. Mol Cell Endocrinol 105:45–53PubMedCrossRef
37.
Zurück zum Zitat Alarid ET, Preisler-Mashek MT, Solodin NM (2003) Thyroid hormone is an inhibitor of estrogen-induced degradation of estrogen receptor-alpha protein: estrogen-dependent proteolysis is not essential for receptor transactivation function in the pituitary. Endocrinology 144:3469–3476PubMedCrossRef Alarid ET, Preisler-Mashek MT, Solodin NM (2003) Thyroid hormone is an inhibitor of estrogen-induced degradation of estrogen receptor-alpha protein: estrogen-dependent proteolysis is not essential for receptor transactivation function in the pituitary. Endocrinology 144:3469–3476PubMedCrossRef
38.
Zurück zum Zitat Cengiz O, Bozkurt B, Unal B, Yildirim O, Karabeyoglu M, Eroglu A, Koçer B, Ulaş M (2004) The relationship between prognostic factors of breast cancer and thyroid disorders in Turkish women. J Surg Oncol 87:19–25PubMedCrossRef Cengiz O, Bozkurt B, Unal B, Yildirim O, Karabeyoglu M, Eroglu A, Koçer B, Ulaş M (2004) The relationship between prognostic factors of breast cancer and thyroid disorders in Turkish women. J Surg Oncol 87:19–25PubMedCrossRef
39.
Zurück zum Zitat Cristofanilli M, Yamamura Y, Kau SW, Bevers T, Strom S, Patangan M, Hsu L, Krishnamurthy S, Theriault RL, Hortobagyi GN (2005) Thyroid hormone and breast carcinoma. Primary hypothyroidism is associated with a reduced incidence of primary breast carcinoma. Cancer 103:1122–1128PubMedCrossRef Cristofanilli M, Yamamura Y, Kau SW, Bevers T, Strom S, Patangan M, Hsu L, Krishnamurthy S, Theriault RL, Hortobagyi GN (2005) Thyroid hormone and breast carcinoma. Primary hypothyroidism is associated with a reduced incidence of primary breast carcinoma. Cancer 103:1122–1128PubMedCrossRef
40.
Zurück zum Zitat Ditsch N, Liebhardt S, Von Koch F, Lenhard M, Vogeser M, Spitzweg C, Gallwas J, Toth B (2010) Thyroid function in breast cancer patients. Anticancer Res 30:1713–1718PubMed Ditsch N, Liebhardt S, Von Koch F, Lenhard M, Vogeser M, Spitzweg C, Gallwas J, Toth B (2010) Thyroid function in breast cancer patients. Anticancer Res 30:1713–1718PubMed
41.
Zurück zum Zitat Cecconi S, Rucci N, Scaldaferri ML, Masciulli MP, Rossi G, Moretti C, D’Armiento M, Ulisse S (1999) Thyroid hormone effects on mouse oocyte maturation and granulosa cell aromatase activity. Endocrinology 140:1783–1788PubMed Cecconi S, Rucci N, Scaldaferri ML, Masciulli MP, Rossi G, Moretti C, D’Armiento M, Ulisse S (1999) Thyroid hormone effects on mouse oocyte maturation and granulosa cell aromatase activity. Endocrinology 140:1783–1788PubMed
42.
Zurück zum Zitat Ulisse S, Jannini EA, Carosa E, Piersanti D, Graziano FM, D’Armiento M (1994) Inhibition of aromatase activity in rat Sertoli cells by thyroid hormone. J Endocrinol 140:431–436PubMedCrossRef Ulisse S, Jannini EA, Carosa E, Piersanti D, Graziano FM, D’Armiento M (1994) Inhibition of aromatase activity in rat Sertoli cells by thyroid hormone. J Endocrinol 140:431–436PubMedCrossRef
43.
Zurück zum Zitat Kuijpens JL, Nyklíctek I, Louwman MW, Weetman TA, Pop VJ, Coebergh JW (2005) Hypothyroidism might be related to breast cancer in post-menopausal women. Thyroid 15:1253–1259PubMedCrossRef Kuijpens JL, Nyklíctek I, Louwman MW, Weetman TA, Pop VJ, Coebergh JW (2005) Hypothyroidism might be related to breast cancer in post-menopausal women. Thyroid 15:1253–1259PubMedCrossRef
44.
Zurück zum Zitat Sandhu MK, Brezden-Masley C, Lipscombe LL, Zagorski B, Booth GL (2009) Autoimmune hypothyroidism and breast cancer in the elderly. Breast Cancer Res Treat 115:635–641PubMedCrossRef Sandhu MK, Brezden-Masley C, Lipscombe LL, Zagorski B, Booth GL (2009) Autoimmune hypothyroidism and breast cancer in the elderly. Breast Cancer Res Treat 115:635–641PubMedCrossRef
45.
Zurück zum Zitat Smyth PP (2003) Role of iodine in antioxidant defence in thyroid and breast disease. BioFactors 19:121–130PubMedCrossRef Smyth PP (2003) Role of iodine in antioxidant defence in thyroid and breast disease. BioFactors 19:121–130PubMedCrossRef
46.
Zurück zum Zitat Tazebay UH, Wapnir IL, Levy O, Dohan O, Zuckier LS, Zhao QH, Deng HF, Amenta PS, Fineberg S, Pestell RG, Carrasco N (2000) The mammary gland iodide transporter is expressed during lactation and in breast cancer. Nat Med 6:871–878PubMedCrossRef Tazebay UH, Wapnir IL, Levy O, Dohan O, Zuckier LS, Zhao QH, Deng HF, Amenta PS, Fineberg S, Pestell RG, Carrasco N (2000) The mammary gland iodide transporter is expressed during lactation and in breast cancer. Nat Med 6:871–878PubMedCrossRef
Metadaten
Titel
Prevalence of breast cancer in thyroid diseases: results of a cross-sectional study of 3,921 patients
verfasst von
Natalie Prinzi
Enke Baldini
Salvatore Sorrenti
Corrado De Vito
Chiara Tuccilli
Antonio Catania
Sabino Carbotta
Renzo Mocini
Carmela Coccaro
Angela Nesca
Marta Bianchini
Enrico De Antoni
Massimino D’Armiento
Salvatore Ulisse
Publikationsdatum
01.04.2014
Verlag
Springer US
Erschienen in
Breast Cancer Research and Treatment / Ausgabe 3/2014
Print ISSN: 0167-6806
Elektronische ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-014-2893-y

Weitere Artikel der Ausgabe 3/2014

Breast Cancer Research and Treatment 3/2014 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.